Abstract: The present invention provides polypeptides, compositions thereof, and methods for use of the polypeptides in treating bacterial infection and for use as disinfectants.
Type:
Application
Filed:
November 1, 2012
Publication date:
October 2, 2014
Applicant:
Arizona Board of Regents of behalf of Arizona State University
Inventors:
Stephen Johnston, Valeriy Domenyuk, Chris Diehnelt
Abstract: The present invention relates to a polypeptide with an amino acid sequence according to SEQ ID NO: 1 and fragments or derivatives thereof. The present invention further relates to fusion proteins comprising said polypeptide and an additional peptide stretch fused to said polypeptide at the N- or C-terminus. Moreover, the present invention relates to nucleic acid molecules encoding said polypeptide or fusion protein, vectors comprising said nucleic acid molecules and host cells comprising either said nucleic acid molecules or said vectors. In addition, the present invention relates to said polypeptide or fusion protein for use as a medicament, in particular for the treatment or prevention of Gram-negative bacterial infections, as diagnostic means, as cosmetic substance or as sanitizing agent.
Abstract: The present invention relates to methods for preventing or treating Human Immunodeficiency Virus (HIV) infection, inflammatory conditions, and graft-versus-host-disease (GVHD) in a subject. Therapeutic compositions of the present invention comprise Leukocidin E (LukE) and/or D proteins or polypeptides. The invention further relates to methods of treating Staphylococcus aureus infection by administering a composition comprising a CCR5 antagonist or any molecule that blocks LukE/D interaction with CCR5+ cells in an amount effective to treat the S. aureus infection in the subject.
Type:
Grant
Filed:
June 19, 2012
Date of Patent:
September 30, 2014
Assignee:
New York University
Inventors:
Victor J. Torres, Derya Unutmaz, Francis Alonzo, III
Abstract: Formulations have been developed to treat or reduce the spread of respiratory infections, especially chronic or drug resistant infections, particularly tuberculosis (TB), severe acute respiratory syndrome (SARS), meningococcal meningitis, Respiratory syncytial virus (RSV), influenza, and small pox. Formulations include a drug or vaccine in the form of a microparticle, nanoparticle, or aggregate of nanoparticles, and, optionally, a carrier, which can be delivered by inhalation. Giving the drugs via an inhaler sidesteps the problems associated with oral or injectable drugs by bypassing the stomach and liver, and delivering the medication directly into the lungs. In one embodiment, the particle containing the agent is a large porous aerosol particle (LPPs). In another embodiment, the particles are nanoparticles, which can be administered as porous nanoparticle aggregates with micron diameters that disperse into nanoparticles following administration.
Type:
Grant
Filed:
October 19, 2005
Date of Patent:
September 30, 2014
Assignee:
President and Fellows of Harvard College
Inventors:
David A. Edwards, Jennifer Fiegel, Jean Sung
Abstract: The present invention relates to new peptides and to use thereof, in particular for treatment and/or prevention of infections, inflammations, pain, wounds, scar and/or tumors.
Type:
Grant
Filed:
January 25, 2012
Date of Patent:
September 30, 2014
Assignee:
Pergamum AB
Inventors:
Margit Mahlapuu, Camilla Björn, Veronika Sjöstrand, Björn Walse, Bo Svenson
Abstract: An antimicrobial peptide having potent antibacterial activity against Listeria monocytogenes and Staphylococcus aureus is described. Also described is an isolated Lactobacillus salivarius DPC6502 strain as deposited with the National Collection of Industrial and Marine Bacteria under the Accession No. NCIMB 41840, and variants thereof, wherein the isolated bacteria and variants thereof express an antimicrobial peptide of the invention.
Type:
Application
Filed:
July 27, 2012
Publication date:
September 25, 2014
Applicants:
AGRICULTURE AND FOOD DEVELOPMENT AUTHORITY (TEAGASC), UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND, CORK
Abstract: The present invention relates to compounds which bind to the hydrophobic pocket of the ? clamp, i.e., to the surface of the ? ring with which said protein interacts with other proteins of the bacterial replication complex during DNA replication. These compounds are derived from the acetylated peptide AcQLDLF (P6) to improve their affinity to their target.
Type:
Application
Filed:
April 13, 2012
Publication date:
September 25, 2014
Applicant:
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Abstract: Novel template-fixed ?-hairpin peptidomimetics of the general formula (I): cyclo[P1-P2-P3-P4-P5-P6-P7-P8-P9-P10-P11-P12-P13-P14-T1-T2] wherein the single elements T or P are ?-amino acid residues connected in either direction which, depending on their positions in the chain, are as defined in the description and the claims, and salts thereof, have the property of antagonizing the biological effect of the receptor FPR1. They can be used as medicaments to treat or prevent diseases or conditions in the areas of inflammatory diseases, allergic conditions, immunological disorders, neuroinflammation, neurological disorders, obstructive airway diseases, infectious diseases, ischemic reperfusion injuries and proliferative disorders such as e.g. cancer. These ?-hairpin peptidomimetics can be manufactured by a process which is based on a mixed solid- and solution phase synthetic strategy.
Type:
Application
Filed:
October 2, 2012
Publication date:
September 25, 2014
Applicant:
POLYPHOR AG
Inventors:
Françoise Jun, Danie Obrecht, Ralf Löwe, Johann Zimmermann, Guillaume Lemercier, Eric Chevalier
Abstract: The present invention relates to compositions and methods to administer compositions comprising cupredoxin and/or cytochrome and/or variants, derivatives, truncations and structural equivalents of cupredoxin and cytochrome to treat and/or prevent two or more conditions in a mammalian cell. The invention also relates to compositions and methods to administer compositions comprising cupredoxin and/or cytochrome and/or variants, derivatives, truncations and structural equivalents of cupredoxin and cytochrome to concurrently treat and/or prevent two or more conditions in a patient such as HIV, cancer, malaria and inappropriate angiogenesis.
Type:
Application
Filed:
December 2, 2013
Publication date:
September 25, 2014
Applicant:
The Board of Trustees of the University of Illinois
Abstract: Provided herein are compositions, which include an active pharmaceutical ingredient and macrogol 15 hydroxystearate, and methods for using the same for treating diseases or disorder.
Type:
Application
Filed:
December 9, 2013
Publication date:
September 25, 2014
Applicant:
ALLERGAN, INC.
Inventors:
ANURADHA V. GORE, KEVIN S. WARNER, CHETAN P. PUJARA, RICHARD S. GRAHAM, AJAY P. PARASHAR, MU-LAN LEE, ROBERT S. JORDAN, SUKHON LIKITLERSUANG
Abstract: The present disclosure serves to reduce the healing time of tissue wounds, including those formed during surgery, whether necessary or elective (including cosmetic surgery), by providing a therapeutic dose of a pancreatic enzyme inhibitor.
Type:
Grant
Filed:
September 28, 2010
Date of Patent:
September 23, 2014
Assignee:
The Regents of The University of California
Inventors:
Frank A. DeLano, Geert W. Schmid-Schonbein
Abstract: The present invention relates to a compound of formula I: wherein x is in the range of from about 1 to about 2. The invention also relates to pharmaceutical compositions containing such compounds; processes for preparing such compounds; and methods of using such compounds to, for example, treat a bacterial infection.
Type:
Application
Filed:
March 6, 2014
Publication date:
September 18, 2014
Applicant:
THERAVANCE, INC.
Inventors:
Weijiang Zhang, Ronnie Cheung, Dimitar Filipov, Jack Green, Junning Lee
Abstract: Provided is a bacterial strain which produces a family of mosquitocidal toxins, Xenorhabdus MT, on deposit with the American Type Culture Collection, PTA-6826, insecticidal compositions comprising the mosquitocidal toxin(s) produced by Xenorhabdus MT, a mosquitocidal toxin preparation prepared from spent culture medium, whole culture or cells or a mixture thereof, of Xenorhabdus MT and method of insect control, especially mosquito control. Also provided are microbial compounds (same as mosquitocidal toxins) compositions comprising them and use in formulating therapeutic and other antimicrobial compositions, and methods of use for inhibiting microbial growth and for treating infection.
Type:
Application
Filed:
March 17, 2014
Publication date:
September 18, 2014
Applicant:
WISCONSIN ALUMI RESEARCH FOUNDATION
Inventors:
Jerald Coleman ENSIGN, Que LAN, David DYER
Abstract: The present application describes organic compounds of Formula (I) and pharmaceutical compositions thereof, and their use for the treatment, prevention and/or amelioration of diseases, particularly bacterial infections.
Type:
Application
Filed:
May 30, 2014
Publication date:
September 18, 2014
Applicant:
NOVARTIS AG
Inventors:
Simon Bushell, Matthew J. Lamarche, Jennifer Leeds, Lewis Whitehead
Abstract: Provided are methods, test devices, and diagnostic kits for predicting, assessing, and diagnosing the risk of a disease using salivary analysis. The methods comprise providing a whole (unfractionated) saliva sample from a subject; contacting an aliquot of the saliva with two or more lectins under conditions that allow the two or more lectins to bind to a lectin-binding component of the saliva; detecting the amount of bound lectin; and comparing the amount of bound lectin to the amount known to bind a saliva sample from a control patient, to predict the risk of a disease in the subject. Also provided are methods for reducing the risk of a disease and a method for assessing the risk of the disease at a defined level.
Type:
Application
Filed:
March 15, 2013
Publication date:
September 18, 2014
Inventors:
Patricia Denny, Paul C. Denny, Mahvash Navazesh
Abstract: The present disclosure provides novel powder daptomycin formulations which have improved chemical stability and faster reconstitution times when in the solid state. Some examples of the compositions comprise daptomycin and sucrose.
Type:
Grant
Filed:
November 23, 2010
Date of Patent:
September 16, 2014
Assignee:
Cubist Pharmaceuticals, Inc.
Inventors:
Sandra O'Connor, Sophie Sun, Gaauri Naik
Abstract: Compositions and methods for activating MK2, augmenting permeability barriers, such as epithelial and/or endothelial barriers, and treating diseases, conditions, disorders, and/or injuries associated therewith, such as pulmonary edema and other lung diseases and injuries are provided herein.
Abstract: In an aspect, the invention relates to compositions and methods for permeabilizing membranes of cells. In an aspect, the invention relates to compositions and methods for killing cells. In an aspect, the invention relates to compositions and methods of permeabilizing the membranes of cancer cells or microbial cells.
Type:
Application
Filed:
August 24, 2012
Publication date:
September 11, 2014
Applicant:
UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC.
Inventors:
Annette Khaled, Rebecca Boohaker, Michael Lee, Jesus Perez Figueroa
Abstract: The present invention provides compositions and methods for noninvasive delivery of therapeutic agents across an intact tympanic membrane. For example, the compositions include a penetration enhancer which increases the flux of a therapeutic agent (e.g., antibiotic) across the tympanic membrane. Such compositions are particularly useful in the treatment of otitis media. Additionally, the composition may include a sustained release agents that, in some embodiments form sustained release reservoirs, in situ, once administered to a patient.
Type:
Grant
Filed:
May 19, 2009
Date of Patent:
September 2, 2014
Assignees:
Children's Medical Center Corporation, Massachusetts Institute of Technology
Inventors:
Emmanuel John Simons, Todd R. Hoare, Daniel S. Kohane, Robert S. Langer
Abstract: The technology described herein relates to treatments for tuberculosis which target the ClpP1P2 protease complex, including ClpC1. Further embodiments relate to assays and screens for modulators of the ClpP1P2 protease complex, including ClpC1.
Type:
Application
Filed:
October 19, 2012
Publication date:
August 28, 2014
Inventors:
Olga Kandror, Alfred Lewis Goldberg, Tatos Akopian, Eric J. Rubin, Ravikiran M. Raju
Abstract: The present invention is directed to a disk diffusion assay for determining susceptibility of bacteria to a glycopeptide antibiotic. The assay includes improvements over conventional assays due to the inclusion of polysorbate 80 and Span 80 in the antibacterial solution used to impregnate paper disks used in the assay.
Abstract: The invention relates to peptide derivatives of general formula (I): R1-AA1-AA2-R3-AA4-R2??(I) their stereoisomers, mixtures thereof, and their cosmetically or pharmaceutically acceptable salts, a method for obtaining them, cosmetic or pharmaceutical compositions containing them and their use for the treatment, care and/or cleansing of those conditions, disorders and/or pathologies of the skin, mucosae, scalp and/or nails resulting from microorganism proliferation or being at risk of microorganism proliferation.
Inventors:
Cristina Carreño Serraïma, Wim Van Den Nest, Ana Sempere Bonete, Antonio Ferrer Montiel, Juan Cebrián Puche, Nuria Alminaña Doménech, David Panyella Costa, José Ginestar González
Abstract: The present invention is directed to the peptides WKWLKKWIK, WRKFWKYLK, and RRWRVIVKW and use of said peptides as therapeutic agents for the prophylaxis and/or treatment of infections, in particular bacterial and/or fungal infections and diseases caused by bacterial and/or fungal infections.
Abstract: The invention provides a method for preventing or treating a disease caused by an extracellular microorganism, said method comprising systemically administering to a subject in need thereof a prophylactically or therapeutically effective amount of a salicylic acid (SAL) or a SAL analogue. The extracellular microorganism can be of the bacterial genus Staphylococcus, for example, Staphylococcus aureus. The extracellular microorganism can be a strain that is resistant to at least one antibiotic. The strain can be selected from the group consisting of methycillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA).
Type:
Grant
Filed:
October 26, 2009
Date of Patent:
August 19, 2014
Assignee:
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center
Abstract: The present invention provides a peptide, peptidomimetic or amino acid derivative having a net positive charge of at least +2 and incorporating a disubstituted ? amino acid, each of the substituting groups in the ? amino acid, which may be the same or different, comprises at least (7) non-hydrogen atoms, is lipophilic and has at least one cyclic group, one or more cyclic groups within a substituting group may be linked or fused to one or more cyclic groups within the other substituting group and where cyclic groups are fused in this way the combined total number of non-hydrogen atoms for the two substituting groups is at least (12), for use as a cytolytic therapeutic agent; as well as non therapeutic uses of these molecules and certain defined novel compounds from within this definition.
Type:
Grant
Filed:
November 2, 2010
Date of Patent:
August 19, 2014
Assignee:
Lytix Biopharma AS
Inventors:
Morten Strom, Terkel Hansen, Martina Havelkova, Veronika Torfoss
Abstract: The invention relates to multimeric forms of antimicrobial peptides, for example, defensin peptides. The multimeric forms of defensin peptides possesses antimicrobial activity and may be formulated into antimicrobial compositions, pharmaceutical compositions, eyedrop composition, contact lens solution compositions for coating medical devices and the like. The invention also relates to the use of these multimeric forms of peptides, e.g. multimeric forms of defensin peptides for inhibiting and/or reducing the growth of microorganisms in general, including in a host. The invention further relates to a method of preparing multimers of peptides derived from defensins, for example hBD3.
Type:
Grant
Filed:
April 21, 2009
Date of Patent:
August 19, 2014
Assignees:
Singapore Health Service Pte Ltd., Agency for Science, Technology and Research
Inventors:
Roger W. Beuerman, Shouping Liu, Jing Li, Lei Zhou, Chandra Shekhar Verma, Donald Tan
Abstract: The present invention generally relates to a novel highly discriminating antibiotic, plantazolicin, a plantazolicin-like compound and to pharmaceutical compositions comprising the same. Also provided are methods for producing and using plantazolicin. Due to its bactericidal activity against Bacillus anthracis, plantazolicin and plantazolicin-like compounds can be used in methods for treating and/or preventing anthrax infections.
Abstract: The present invention provides methods and compositions (such as pharmaceutical compositions) comprising PAR1 antagonists for treating or preventing influenza virus type A infections, in particular H1N1 infection. PAR1 antagonists may be combined with a PAR2 agonist.
Type:
Grant
Filed:
November 15, 2010
Date of Patent:
August 12, 2014
Assignee:
Institut National de la Recherche Agronomique
Abstract: The present disclosure provides antimicrobial peptides, and compositions comprising same. The present disclosure further provides methods of inhibiting microbial growth.
Type:
Application
Filed:
April 16, 2012
Publication date:
August 7, 2014
Applicant:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Inventors:
Suzanne M.J. Fleiszig, David J. Evans, Kwai Ping Tam, James J. Mun
Abstract: The present invention provides methods for preventing, treating, or reducing the severity of infection, including bacterial, viral, and fungal infections, and including infections of more complex etiology. The invention involves the administration of an alpha thymosin peptide regimen, so as to prime or enhance a patient's immune response for pathogen exposure. In certain embodiments, the alpha thymosin regimen is scheduled or timed with respect to potential or expected pathogen exposures. The regimen of alpha thymosin peptide as described herein provides the patient with a more robust immune response to pathogen exposure, including higher antibody titers and/or a more rapid antibody response. In certain embodiments, the patient is immunodeficient or immunecompromised, and/or the patient is hospitalized or scheduled for hospitalization, such that the regimen of alpha thymosin peptide helps to protect the patient from, or reduce the severity of nosocomial infection or illness.
Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of respiratory tract infections. More particularly, the present invention relates to a TLR5 agonist for use in a method for treating a respiratory tract infection.
Type:
Application
Filed:
February 20, 2014
Publication date:
July 24, 2014
Applicants:
Institut Pasteur de Lille, Institut National de la Sante et de la Recherche Medicale (INSERM)
Inventors:
Jean-Claude Sirard, Jose A. Chabalgoity
Abstract: The present invention relates generally to dental diseases, caries and periodontal disease. More specifically, the invention relates to Lactoferrin and PAK fusion peptides (PAK-LF), along with therapeutic, diagnostic and research uses for these polypeptides. The present invention also provides methods of treating dental diseases, caries and periodontal disease.
Type:
Application
Filed:
April 23, 2012
Publication date:
July 10, 2014
Applicant:
RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
Abstract: The invention relates to a compound of the general structure (I), where R is a hydrogen atom (II) or an unsubstituted, monosubstituted or polysubstituted C1-C20-alkyl, wherein the alkyl is straight, branched, cyclic and/or partially unsaturated, or an unsubstituted, monosubstituted or polysubstituted phenyl group.
Type:
Grant
Filed:
April 30, 2010
Date of Patent:
July 1, 2014
Assignee:
Geomar Helmholtz-Zentrum fur Ozeanforschung Kiel
Inventors:
Johannes Imhoff, Inga Knopf-Kajahn, Gerhard Lang, Jutta Wiese, Arne Peters
Abstract: The present invention provides methods for the prophylactic and therapeutic amelioration and treatment of gram-positive bacteria in companion animals and livestock, including Streptococcus and Staphylococcus bacterial strains, including pathogenic and antibiotic-resistant bacteria, and related conditions. The methods of the invention utilize PlySs2 and/or PlySs1 lytic enzymes and variants thereof, including truncations thereof. Methods for treatment of companion animals and livestock are provided.
Type:
Application
Filed:
April 20, 2012
Publication date:
June 26, 2014
Applicants:
THE ROCKEFELLER UNIVERSITY, UNIVERSITEIT UTRECHT HOLDING BV
Inventors:
Vincent A. Fischetti, Jonathan Schmitz, Daniel Gilmer, Jacob Anthony Wagenaar, Jan Arend Stegeman
Abstract: The present invention relates to fluorocarbon vectors for the delivery of antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals.
Type:
Grant
Filed:
January 20, 2012
Date of Patent:
June 24, 2014
Assignee:
Immune Targeting Systems Ltd.
Inventors:
Dominique Bonnet, Carlton B. Brown, Bertrand Georges, Philip J. Sizer
Abstract: This invention provides novel targeted antimicrobial compositions. In various embodiments chimeric moieties are provided comprising an antimicrobial peptide attached to a peptide targeting moiety that binds a bacterial strain or species.
Type:
Grant
Filed:
January 6, 2010
Date of Patent:
June 17, 2014
Assignee:
C3 Jian, Inc.
Inventors:
Randal H. Eckert, Chris Kaplan, Jian He, Daniel K. Yarbrough, Maxwell Anderson, Jee-Hyun Sim
Abstract: Peptide compounds based on the CAP37 protein are disclosed, along with methods for treating various infections, wounds, and conditions, and methods of promoting healing and acceptance of grafts, using compositions containing these peptides.
Type:
Application
Filed:
December 3, 2013
Publication date:
June 12, 2014
Applicant:
The Board of Regents of the University of Oklahoma
Abstract: We describe a method for mining microbial genomes to discover antimicrobial genes and proteins having broad spectrum of activity. Also described are antimicrobial genes and their expression products from various microbial genomes that were found using this method. The products of such genes can be used as antimicrobial agents or as tools for molecular biology.
Type:
Application
Filed:
August 1, 2013
Publication date:
June 12, 2014
Applicant:
The Regents of the University of California
Abstract: Compositions comprising an isolated peptide, which may for example optionally comprise a sequence selected from the group consisting of FDYDWY (SEQ ID NO: 2), SFSQNKSVHSFDYDWYNVSDQADLKN (SEQ ID NO: 3) or CSFSQNKSVHSFDYDWYNVSDQADLKNC (SEQ ID NO: 1), or any cyclized version thereof, and methods of using same, including for treatment of or prevention of formation of microbial biofilms and against adhesion of a cell to a surface.
Type:
Application
Filed:
September 3, 2013
Publication date:
June 5, 2014
Applicant:
Tel Hashomer Medical Research, Infrastructure and Services Ltd.
Abstract: The present application discloses a method for treating microbial infection using an antimicrobial composition comprises antimicrobial peptide which contains at least one VGFPV motif.
Type:
Application
Filed:
January 15, 2014
Publication date:
June 5, 2014
Applicant:
MOREHOUSE SCHOOL OF MEDICINE
Inventors:
VINCENT CRAIG BOND, MICHAEL POWELL, MING BO HUANG, SYED ALI, MARTIN NEVILLE SHELTON
Abstract: Disclosed herein is a peptide for inhibiting growth of bacterial pathogens in a biological sample, characterized by an amino acid sequence selected from a group consisting of Pro-His-Trp-Trp-Lys-Trp-Ala-Trp-Trp-His-His-Arg-Arg (SEQ ID NO:1), Lys-His-Trp-Trp-Lys-His-Asp-Trp-Trp-Arg-Trp-Arg-Arg (SEQ ID NO:2), and Ile-Leu-Trp-Trp-Leu-Leu-Ala-Trp-Trp-Arg-Trp-Pro-His (SEQ ID NO:3).
Type:
Grant
Filed:
June 18, 2013
Date of Patent:
June 3, 2014
Assignee:
Universiti Malaya
Inventors:
Shamala Devi Sekaran, Mohd Yasim Md Yusof, Cheng Foh Le
Abstract: Disclosed herein is a peptide for inhibiting growth of bacterial pathogens in a biological sample, characterized by an amino acid sequence selected from a group consisting of Gly-Leu-Phe-Asp-Lys-Trp-Ala-Trp-Trp-Arg-Trp-Arg-Arg (SEQ ID NO:1), Gly-Leu-Phe-Asp-Ile-Trp-Ala-Trp-Trp-Arg-Trp-Arg-Arg (SEQ ID NO:2), Gly-Leu-Phe-Asp-Ile-Trp-Lys-Trp-Trp-Arg-Trp-Arg-Arg (SEQ ID No:3), Gly-Leu-Phe-Asp-Ile-Trp-Lys-Lys-Trp-Arg-Trp-Arg-Arg (SEQ ID NO:4), and Gly-Leu-Phe-Asp-Ile-Trp-Lys-Lys-Leu-Arg-Trp-Arg-Arg (SEQ ID NO:5).
Type:
Grant
Filed:
June 18, 2013
Date of Patent:
June 3, 2014
Assignee:
Universiti Malaya
Inventors:
Shamala Devi Sekaran, Mohd Yasim Md Yusof, Cheng Foh Le
Abstract: A method of controlling unwanted bacteria in fermentation processes comprising contacting reactants of the process with an effective amount of bacteriocin. Bacteriocin, both indigenous and produced from independent sources, and optionally bacteriocin plus bacteriophages virulent for unwanted bacteria are used to reduce and control unwanted bacteria.
Abstract: The present invention relates to antibacterial peptides and analogs thereof, e.g., originating from, derived from, isolated and/or purified from mammalian milk, that reduce, inhibit and/or prevent the growth or proliferation of a bacterial organism.
Type:
Application
Filed:
March 1, 2013
Publication date:
May 29, 2014
Applicant:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Inventor:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Abstract: The present invention relates to, inter alia, a method for repressing transcription and/or gene expression from RpoN binding sites (or promoters) or cryptic promoters upstream of RpoN binding sites. The method comprises providing an agent that specifically and selectively binds to RpoN promoter sequences to inhibit or repress the expression of genes downstream of that promoter; and contacting the RpoN promoter with the agent. Agents for repressing transcription and/or gene expression from RpoN promoters are also provided. The agent can be a composition that binds specifically to the ?24, ?12, or ?24/?12 site(s) for RpoN promoter interference. Synthetic peptides, vectors, and host cells are also provided.
Type:
Application
Filed:
May 7, 2012
Publication date:
May 29, 2014
Applicant:
THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK
Inventors:
Christopher T. Nomura, Benjamin R. Lundgren
Abstract: Pre-implantation factor (PIF) may be used to treat intracellular damage. Aspects of the invention are directed to a method of treating intracellular damage comprising administering PIF to a subject in need thereof. Some aspects may be directed to methods of increasing cytokine secretion in response to intracellular damage comprising administering PIF to a subject in need thereof. The intracellular damage may be a result of a disease such as Listeria monocytogenes infection, malaria, Lyme disease, cardiovascular disease, duodenal peptic ulcer, atherosclerosis, peritonitis or tuberculosis. In some aspects, a method of treating tuberculosis is disclosed, comprising administering PIF to a subject in need thereof. In some aspects, a method of treating atherosclerosis is disclosed, comprising administering PIF to a subject in need thereof. In some aspects, a method of treating peritonitis is disclosed, comprising administering PIF to a subject in need thereof.
Abstract: Characterization of the biosynthetic gene cluster for the lantibiotic actagardine, identification of a novel variant of actagardine and its biosynthetic cluster, and methods of production and use of actagardine are described.
Type:
Grant
Filed:
December 4, 2012
Date of Patent:
July 8, 2014
Assignee:
Novacta Biosystems Limited
Inventors:
Steven Boakes, Jesus Cortes Bargallo, Michael John Dawson